Our three-pronged strategy to success

We believe a well-thought strategy is essential to maintain profitability and growth, increase efficiency and speed to market, improve cost competitiveness and achieve delayering. Over the years, we have refined a three-pronged interlinked strategy that helps us remain on the path to success. It combines leadership, operational excellence and patient-centric innovation.

Leadership in chosen spaces
We want to be the undisputed leaders in Biologics and Pharmaceutical Services and APIs in the markets we are active in — India, North America, Russia, China and Europe. To achieve this goal, we continuously action initiatives that enable us to improve customer engagement, remain agile in our businesses and grow our market share.

Operational excellence and continuous improvement
We aim to set benchmarks in operational excellence across research, manufacturing and customer engagement. To do this, we make great efforts to consistently improve quality, productivity and effectiveness across the value chain. Over the past year, we have harnessed the power of technology to implement a digital transformation that will augment our efforts to improve continuously and achieve our goal of operational excellence.

Patient-centric product innovation
We have always been committed to providing patients around the world with solutions that will help them through the treatment journey. Our Proprietary Products division is constantly developing formulations and delivery mechanisms that seek to help patients manage their diseases better. In FY2020 alone, we filed eight Abbreviated New Drug Applications with the US Food and Drug Administration.

The effectiveness of this strategy is borne out by the financial results for FY2020.
• Our consolidated revenues were $2.5 billion, or a 13% growth over the previous year. This was on top of an 8% growth in FY2019.
• Our consolidated gross profit was $1.3 billion, which was 13% greater than the previous year. This, too, came over and above a 9% growth in FY2019.

And it’s not just hard numbers. Our growing community of patients, partners, HCPs and employees globally shows that our strategy is working. As we continue on this path, we are determined to build the world with us.

‍